Fluidigm Corp develops, manufactures, and markets microfluidic systems. The Company provides its products to academic institutions, clinical laboratories, and pharmaceutical, biotechnology and Ag-Bio companies in markets, such as single-cell genomics, applied genotyping, and sample preparation. The Company’s microfluidic systems consist of instruments and consumables, including integrated fluidic circuits (IFCs), assays, and reagents. The Company markets four microfluidic systems, including 18 different commercial IFCs, and three families of assay chemistries. The Company’s BioMark HD System performs gene expression analysis, single-cell targeted gene expression analysis, SNP genotyping and digital PCR. C1 Single-Cell Auto Prep System enables isolation, processing, and profiling of individual cells for genomic analysis. The EP1 System performs SNP genotyping using Fluidigm SNPtype assays or TagMan assays, and end-point digital PCR.